NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)

An FDA Adverse Events Reporting System (FAERS) database analysis of adverse events experienced among patients age < 65 and those age > 65 receiving axicabtagene ciloleucel and/or tisagenlecleucel CAR T-cell therapy showed that some individual clinical features of cytokine release syndrome were significantly more common among younger age group cases, including tachycardia (10% vs. 5%, p < .01).